SCHEMBL24257699

SCHEMBL24257699

CCOC(=O)CNC(=O)c1ncc(-c2cnn(-c3ccccc3)c2)c(C)c1O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.44
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
GRM4 Q14833 5/20 0.43
ALDH1A1 P00352 2/20 0.42
CCNC P24863 1/20 0.42
CDK8 P49336 1/20 0.42
EGLN1 Q9GZT9 1/20 0.41
GAA P10253 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLQ O75417 1/20 0.40
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PPID Q08752 1/20 0.39
DGAT1 O75907 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257767 0.91 NPC1 (0.41) HPGDRAB9ANPC1GRM4ALDH1A1
SCHEMBL24257828 0.91 EGLN1 (0.43) HPGDRAB9ANPC1ALDH1A1EGLN1
SCHEMBL30453229 0.89 EGLN1 (0.51) GRM4ALDH1A1EGLN1LMNA
SCHEMBL24257610 0.89 EGLN1 (0.51) GRM4ALDH1A1EGLN1LMNA
SCHEMBL24257711 0.88 GRM4 (0.48) HPGDRAB9ANPC1GRM4ALDH1A1
SCHEMBL26259968 0.88 ALDH1A1 (0.42) HPGDRAB9ANPC1GRM4ALDH1A1
SCHEMBL24257745 0.87 GRM4 (0.42) HPGDRAB9ANPC1GRM4ALDH1A1
SCHEMBL24257715 0.84 EGLN1 (0.53) HPGDRAB9ANPC1ALDH1A1EGLN1
SCHEMBL24257820 0.84 HPGD (0.46) HPGDRAB9ANPC1GRM4ALDH1A1
SCHEMBL24257842 0.83 EGLN1 (0.52) RAB9ANPC1EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 HPGD 109/4885RAB9A 739/4885NPC1 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.